Thursday, October 8, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 23, 2025

The Zacks Analyst Blog Highlights Ericsson, Nokia and CommScope

View original at finance.yahoo.com
The Zacks Analyst Blog Highlights Ericsson, Nokia and CommScope For Immediate Release Chicago, IL – December 23, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Ericsson has a long-term earnings growth expectation of 8.44%

    80% confidence

  • CommScope delivered an earnings surprise of 143.98%, on average, in the trailing four quarters

    80% confidence

  • Shares of mobile data carried over 5G are expected to grow from 34% in 2024 to 83% in 2031

    80% confidence

  • 5G technology is essential for national security

    80% confidence

  • Ericsson delivered an earnings surprise of 13.51%, on average, in the trailing four quarters

    80% confidence

  • CommScope has a long-term earnings growth expectation of 13.48%

    80% confidence

  • Mobile data traffic is expected to witness a 16% CAGR from 2024 to 2031

    80% confidence

  • 5G subscriptions in Southeast Asia and Oceania are projected to reach around 680 million in 2031

    80% confidence

  • The 5G services market is expected to witness a 62.2% CAGR between 2025 and 2030

    80% confidence

  • The 5G infrastructure market is expected to witness a 13.1% compound annual growth rate between 2026 and 2033

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com
The Zacks Analyst Blog Highlights Ericsson, Nokia and CommScope — Source | Via News | ViaNews Market